Ether Oxygen Is Part Of The Chain Patents (Class 514/651)
-
Publication number: 20140248236Abstract: The disclosure provides methods of use of certain compounds that are useful for treating certain symptoms of endocrine disturbances, and in particular those associated with hot flashes.Type: ApplicationFiled: November 7, 2012Publication date: September 4, 2014Inventors: Michael G. Natchus, Richard Arrendale
-
Publication number: 20140243379Abstract: Transdermal drug delivery patches and methods of their production are described. The patches can be made such that the accommodate highly plasticizing drugs such as selegiline and/or the use of protonated forms of various drugs.Type: ApplicationFiled: May 7, 2014Publication date: August 28, 2014Applicant: MYLAN TECHNOLOGIES, INC.Inventors: Sharad K. Govil, Ludwig J. Weimann
-
Publication number: 20140234428Abstract: The invention, a transdermal delivery method, relates to penetration-enhancing pharmaceutical compositions comprising a novel, stable mixture of cetylated esters, cetyl or stearyl alcohols, polar solvents and surfactants, which, under appropriate conditions, combine into amphiphilic nanoparticles within a stabilized liquid dispersion for use in delivery of medicinal agents through the skin. The term cetosomes is used to describe these particles in order to differentiate them from other nanoparticles, such as niosomes, cerasomes, polymeric micelles, dendrimers, liposomes, lipoids, solid lipid nanoparticles and other particles. The self-assembling cetosomes, with both ionic and nonionic points of attraction, incorporate and concentrate a variety of different bioactive agents of interest and demonstrate stable properties with similarities to colloidal molecular structures. The compositions enhance topical transdermal fluxes of bioactives without permanently disrupting natural skin barrier function.Type: ApplicationFiled: February 15, 2013Publication date: August 21, 2014Applicant: Cymbiotics, Inc.Inventors: Raj R. Barathur, Jack Bain Bookout
-
Publication number: 20140228402Abstract: The invention relates to a combination which comprises fingolimod and at least antidepressant compound.Type: ApplicationFiled: September 7, 2012Publication date: August 14, 2014Applicant: Novartis AGInventors: Matthias Meergans, Ferenc Tracik, Katrin Schuh
-
Publication number: 20140221353Abstract: The invention relates to methods for detecting the oncogenic condition of cells, including step where the amount of the OCDO compound in said cells is measured, and to the uses thereof. The invention further relates to OCDO inhibitors for use in methods for treating cancer.Type: ApplicationFiled: December 5, 2013Publication date: August 7, 2014Applicants: Affichem, INSERM (Institut National de la Sante et de la Recherche Medicale)Inventors: Philippe De Medina, Michael Paillasse, Marc Poirot, Sandrine Silvente-Poirot
-
Publication number: 20140221496Abstract: The invention provides diagnostic and therapeutic methods for neoplastic disease patients with neoplasms of, for example, the breast, skin, kidney, lung, pancreas, rectum and colon, prostate, bladder, epithelial, non-epithelial, lymphomas, sarcomas, melanomas, and the like, wherein the method comprises determining the level of expression o caveolin-1, caveolin-2, vimentin, calponin2, tropomyosin, gelsolin, prolyl 4-hydroxylase alpha, EF-I-delta, or M2-isoform of pyruvate kinase in stromal cells adjacent to the neoplasm.Type: ApplicationFiled: November 26, 2013Publication date: August 7, 2014Inventors: Michael P. Lisanti, Federica Sotgia, Richard G. Pestell
-
Publication number: 20140221286Abstract: It is discovered that sodium-channel blockers inhibit the secretion of glucagon from pancreatic alpha cells. The present disclosure, based on such discoveries, provides compositions and methods for the treatment of hyperglycemia and related diseases and conditions with Na-channel blockers.Type: ApplicationFiled: September 20, 2012Publication date: August 7, 2014Inventors: Luiz Belardinelli, Arvinder Dhalla
-
Publication number: 20140221384Abstract: The present invention relates to nordihydroguaiaretic acid derivative compounds, namely, butane bridge modified nordihydroguaiaretic acid (NDGA) compounds and butane bridge modified tetra-O-substituted NDGA compounds, pharmaceutical compositions containing them, methods of making them, and methods of using them and kits including them for the treatment of diseases and disorders, in particular, diseases resulting from or associated with a virus infection, such as HIV infection, HPV infection, or HSV infection, an inflammatory disease, such as various types of arthritis and inflammatory bowel diseases, metabolic diseases, such as diabetes and hypertension, or a proliferative disease, such as diverse types of cancers.Type: ApplicationFiled: April 7, 2014Publication date: August 7, 2014Applicant: ERIMOS PHARMACEUTICALS LLCInventors: Jonathan Daniel Heller, Qingqi Chen, Rocio Alejandra Lopez, Amanda Jean Morris
-
Methods of Using Rapid-Onset Selective Serotonin Reuptake Inhibitors for Treating Sexual Dysfunction
Publication number: 20140221497Abstract: Methods for the prevention, treatment, or management of sexual dysfunction, such as premature ejaculation, by administering to a patient in need of therapy a therapeutically effective amount of a rapid-onset selective serotonin reuptake inhibitor on an as-needed basis shortly before sexual activity.Type: ApplicationFiled: April 10, 2014Publication date: August 7, 2014Applicant: APBI Holdings, LLC.Inventor: Karl Bruce Thor -
Publication number: 20140213617Abstract: Provided are alkynyl phenyl derivative compounds, pharmaceutical compositions thereof, and methods of treating ophthalmic diseases and disorders, such as age-related macular degeneration and Stargardt's Disease, using said compounds and compositions.Type: ApplicationFiled: January 23, 2014Publication date: July 31, 2014Applicant: ACUCELA INC.Inventors: Ian Leslie Scott, Vladimir Aleksandrovich Kuksa, Mark W. Orme, Thomas Little, Anna Gall, Jennifer Gage, Feng Hong
-
Publication number: 20140206770Abstract: Disclosed is the use of at least one amine oxidase inhibitor for modulating the activity of the lysine-specific demethylase (LSD1) in a mammal and to pharmaceutical compositions for controlling the androgen receptor-dependent gene expression, comprising an effective dose of at least one amine oxidase inhibitor suitable for modulating the activity of the lysine-specific demethylase (LSD1) in a mammal.Type: ApplicationFiled: February 4, 2014Publication date: July 24, 2014Applicant: UNIVERSITAETSKLINIKUM FREIBURGInventors: Roland SCHUELE, Eric METZGER
-
Patent number: 8785501Abstract: A particularly constructed tamoxifen-melatonin hybrid ligand gives new and unexpectedly improved results in the prevention and treatment of cancer, particularly breast cancer. The hybrid ligand comprises either tamoxifen or 4-hydroxytamoxifen and also melatonin, with the tamoxifen or 4-hydroxytamoxifen and melatonin's being linked by an unsubstituted C2-C6 alkyl linker between the tamoxifen amine and the carbonyl of melatonin.Type: GrantFiled: October 12, 2010Date of Patent: July 22, 2014Assignee: Duquesne University of the Holy SpiritInventors: Paula A. Witt-Enderby, Vicki L. Davis, David Lapinsky
-
Publication number: 20140200239Abstract: The present invention provides new compounds of formula I, II or III, which have Src homology-2 containing protein tyrosine phosphatase-1 (SHP-1) agonist activity. Also provided are treatment methods using the compounds of formula I, II or III.Type: ApplicationFiled: August 3, 2012Publication date: July 17, 2014Applicant: National Taiwan UniversityInventors: Chung-Wai Shiau, Kuen-Feng Chen
-
Publication number: 20140200516Abstract: Buccal aerosol sprays or capsules using polar and non-polar solvent have now been developed which provide biologically active compounds for rapid absorption through the oral mucosa, resulting in fast onset of effect. The buccal polar compositions of the invention comprise formulation I: aqueous polar solvent, active compound, and optional flavoring agent; formulation II; aqueous polar solvent, active compound, optionally flavoring agent, and propellant; formulation III: non-polar solvent, active compound, and optional flavoring agent; and formulation IV: non-polar solvent, active compound, optional flavoring agent, and propellant.Type: ApplicationFiled: March 18, 2014Publication date: July 17, 2014Applicant: ABBOTT LABORATORIESInventor: Harry A. DUGGER, III
-
Publication number: 20140194479Abstract: The present invention provides, inter alia, methods for enhancing the anti-depressant efficacy of a selective serotonin re-uptake inhibitor (SSRI) in a patient being treated for a mood disorder. These methods include administering to a patient in need thereof a therapeutically effective amount of an SSRI and a therapeutically effective amount of a modulator of histone expression. Also provided are methods for identifying a patient population that suffers from a mood disorder that is more likely to respond to SSRI treatment. Further provided are compositions for treating or ameliorating the effects of a mood disorder.Type: ApplicationFiled: March 13, 2014Publication date: July 10, 2014Inventors: Claudia SCHMAUSS, Amir LEVINE
-
Patent number: 8759350Abstract: The pharmaceutical composition of the present invention comprises (1) a carbostyril derivative and (2) a serotonin reuptake inhibitor in a pharmaceutically acceptable carrier. The carbostyril derivative may be aripiprazole or a metabolite thereof, which is a dopamine-serotonin system stabilizer. The serotonin reuptake inhibitor may be fluoxetine, duloxetine, venlafaxine, milnacipran, citalopram, fluvoxamine, paroxetine, sertraline or escitalopram. The pharmaceutical composition of the present invention is useful for treating patients with mood disorders, particularly depression or major depressive disorder.Type: GrantFiled: December 25, 2003Date of Patent: June 24, 2014Assignee: Otsuka Pharmaceutical Co., Ltd.Inventors: Tetsuro Kikuchi, Taro Iwamoto, Tsuyoshi Hirose
-
Publication number: 20140163114Abstract: The present invention relates to substantially pure metabolites of irara-clomiphene. The invention is also directed to pharmaceutical compositions comprising these metabolites and their use in treating disorders including secondary hypogonadism, type 2 diabetes, elevated cholesterol, elevated triglycerides, wasting, lipodystrophy, female and male infertility, benign prostate hypertrophy, prostate cancer, breast cancer, ovarian cancer and endometrial cancer.Type: ApplicationFiled: August 3, 2012Publication date: June 12, 2014Applicant: REPROS THERAPEUTICS INC.Inventors: Joseph S. Podolski, Ronald D. Wiehle
-
Publication number: 20140135302Abstract: Methods, compositions, and kits for predicting whether a subject with chronic obstructive pulmonary disease (COPD) or at risk of developing COPD is likely to have progressive COPD are provided. Methods, compositions, and kits for predicting whether lung function is likely to decline in a subject with COPD or at risk for developing COPD are also provided.Type: ApplicationFiled: November 7, 2013Publication date: May 15, 2014Applicant: SOMALOGIC, INC.Inventors: Malti P. Nikrad, Stuart G. Field, Stephen Alaric Williams, Alex A.E. Stewart, Rachel M. Ostroff, Rosalynn Dianne Gill
-
Publication number: 20140134254Abstract: A method for producing powders for inhalation includes a first mixing step of stirring a first active ingredient and a carrier in the presence of a milling medium, and mixing the first active ingredient and the carrier while crumbling the agglomerates of the first active ingredient to obtain a mixture of the carrier and the first active ingredient; and a second mixing step of adding fine powders to the mixture obtained in the first mixing step, and stirring and mixing the mixture and the fine powders in the presence of a milling medium.Type: ApplicationFiled: February 25, 2013Publication date: May 15, 2014Inventor: Shinichi Ono
-
Patent number: 8722085Abstract: Methods and systems for administration of pharmaceuticals using a unit dosage package that includes a first unit dosage that has a first drug and a second drug, a second unit dosage that has the first drug and the second drug, where the second unit dosage includes a different amount of the second drug than the first unit dosage and a unit dosage package is configured to hold the first unit dosage and the second unit dosage. In preferred embodiments the methods and systems are used for administration of weight loss medications.Type: GrantFiled: July 16, 2010Date of Patent: May 13, 2014Assignee: Orexigen Therapeutics, Inc.Inventors: Anthony McKinney, Gary Tollefson, Eckard Weber, Rick Soltero
-
Publication number: 20140128360Abstract: The present invention relates to novel substituted phenoxyethylamine derivatives, useful as modulators of cortical and basal ganglia dopaminergic and N-methyl-D-aspartate (NMDA) receptor-mediated glutamatergic neurotransmission. In other aspects the invention relates to the use of these compounds in a method for therapy and to pharmaceutical compositions comprising the compounds of the invention.Type: ApplicationFiled: April 17, 2012Publication date: May 8, 2014Applicant: Integrative Research Laboratories Swenden ABInventors: Clas Sonesson, Jonas Karlsson, Peder Svensson
-
Patent number: 8715709Abstract: Biocompatible intraocular implants include a beta adrenergic receptor antagonist and a polymer associated with the beta adrenergic receptor antagonist to facilitate release of the beta adrenergic receptor antagonist into an eye for an extended period of time. The beta adrenergic receptor antagonist may be associated with a biodegradable polymer matrix, such as a matrix of a two biodegradable polymers. The implants may be placed in an eye to treat one or more ocular conditions, such as an ocular neuropathies, for example, various forms of glaucoma.Type: GrantFiled: November 29, 2010Date of Patent: May 6, 2014Assignee: Allergan, Inc.Inventors: Glenn T. Huang, Thierry Nivaggioli
-
Publication number: 20140121193Abstract: The invention provides methods for treating or ameliorating cognitive dysfunction, fatigue, energy, concentration, mood, and pain associated with fibromyalgia using compositions containing methylphenidate or pharmaceutically equivalents thereof.Type: ApplicationFiled: November 1, 2013Publication date: May 1, 2014Inventors: Robert S. KATZ, Frank LEAVITT
-
Patent number: 8703193Abstract: The present invention relates to controlled porous osmotic pump tablets of high permeable drugs and the preparation process thereof. The controlled porosity osmotic pump tablets do not need to be drilled by laser, but provides controlled porosity for drug release by adding a suitable quantity of pore-forming agents into the semipermeable membrane. In specific embodiments, the present invention relates to controlled porous osmotic pump tablets comprising venlafaxine or metoprolol or pharmaceutically acceptable salts thereof.Type: GrantFiled: October 16, 2007Date of Patent: April 22, 2014Assignee: Cosci Med-Tech Co. Ltd.Inventors: Jingang Wang, Haisong Jiang
-
Publication number: 20140107104Abstract: The present invention provides a combination medicine for treatment of depression, comprising a combination of (A1) an antidepressant and either (B1) a dopamine D1 receptor agonist or (C1) a dopamine D1 receptor antagonist; and a method for screening for an antidepressant that in combination with a dopamine D1 receptor agonist provides an improvement in treatment of depression, the method comprising the steps of: administering, to a mammal, (A2) a compound having an antidepressant action and (B1) a dopamine D1 receptor agonist, and detecting a greater increase in depression-related gene expression, dopamine D1 receptor expression and/or dopamine D1 receptor signaling in comparison with the case where (A2) the compound having an antidepressant action or (B1) the dopamine D1 receptor agonist is administered.Type: ApplicationFiled: March 22, 2012Publication date: April 17, 2014Inventors: Akinori Nishi, Katsunori Kobayashi, Tsuyoshi Miyakawa, Paul Greengard
-
Publication number: 20140100183Abstract: The present invention concerns compositions, methods and/or apparatus of central administration of various CNS-active agents. In particular embodiments, intrathecal administration is advantageous for decreasing the systemic concentrations of CNS agent, thereby decreasing side effect toxicity, while allowing more effective delivery of the agent to the site of action, simultaneously decreasing the dosage delivered to the subject. In particular embodiments, ICV delivery may be of use for patients who have previously proven to be refractory to systemic administration of CNS agents, in some cases due to systemic side effects, or for those patients whose symptoms are of sufficient severity to warrant more aggressive therapeutic intervention. ICV administration allows not only lower systemic concentration but also higher therapeutically effective concentration within the CNS.Type: ApplicationFiled: April 12, 2013Publication date: April 10, 2014Applicant: The Regents of the University of Colorado, a body corporateInventors: Daniel J. ABRAMS, Raymond BUNCH, Tom ANCHORDOQUY, Karen E. STEVENS
-
Publication number: 20140086911Abstract: Provided herein are products, uses and method classifying a subject afflicted with breast cancer according to a ClinicoMolecular Triad Classification (CMTC)-1, CMTC-2 or CMTC-3 class. The method involves: (i) determining a subject expression profile, said subject expression profile comprising the mRNA expression levels of a plurality of genes that classify breast cancer into three groups by hierarchal clustering TN and Her2+ breast cancers into one class (CMTC genes), in a breast cancer cell sample taken from said subject; (ii) calculating a measure of similarity between said subject expression profile, and one or more of: a) a CMTC-1 reference profile, b) a CMTC-2 reference profile, and c) a CMTC-3 reference profile; and (iii) classifying said subject.Type: ApplicationFiled: September 20, 2013Publication date: March 27, 2014Applicant: University Health NetworkInventors: Wey Liang Leong, Dong-Yu Wang, David R. McCready, Susan Jane Done
-
Publication number: 20140080873Abstract: The present invention relates to new compositions and methods for protecting neuronal cells from ischemic or hypoxic events. More precisely, this invention provides new combinatorial therapies that efficiently protect neuronal cells from ischemia or hypoxia.Type: ApplicationFiled: March 1, 2012Publication date: March 20, 2014Applicant: PHARNEXTInventors: Daniel Cohen, Ilya Chumakov, Serguei Nabirochkin, Emmanuel Vial, Mickaël Guedj
-
Publication number: 20140072571Abstract: Disclosed are methods of identifying subjects with osteoporosis or osteopenia, subjects at risk for developing osteoporosis, osteopenia, and bone fractures, methods of evaluating the effectiveness of osteoporosis treatments in subjects with osteoporosis or osteopenia, and methods of selecting therapies for treating osteoporosis or osteopenia, using biomarkers.Type: ApplicationFiled: March 11, 2013Publication date: March 13, 2014Applicant: TETHYS BIOSCIENCE, INC.Inventors: Mickey S. Urdea, Michael P. McKenna, Patrick A. Arensdorf
-
Publication number: 20140051693Abstract: Cerebral palsy impaired speech in children and adolescents are effectively treated by administration of a psychostimulant. Low doses of the psychostimulant significantly increases the percentage of correctly pronounced intelligible syllables or words and the ability to more intelligibly communicate. The improvement in speech persists after cessation of or prior to continued psychostimulant treatment.Type: ApplicationFiled: October 22, 2013Publication date: February 20, 2014Inventors: Bruce Roseman, Gilla Kaplan
-
Publication number: 20140039048Abstract: Methods are provided herein for the treatment of ophthalmic diseases or conditions such as an ophthalmic disease or disorder associated with diabetes in a patient. Also provided herein are methods of treating retinopathy of prematurity in a patient. Further, provided herein are methods for treating wet age-related macular degeneration in a patient. The methods comprise administration of compounds disclosed herein to a patient in need thereof that inhibit or slow one or more signs or symptoms of such conditions.Type: ApplicationFiled: May 3, 2013Publication date: February 6, 2014Applicant: Acucela Inc.Inventor: Acucela Inc.
-
Publication number: 20140038927Abstract: The present invention relates to compositions and methods for the treatment of neurological disorders related to glutamate excitotoxicity and Amyloid ? toxicity. More specifically, the present invention relates to novel combinatorial therapies of Multiple Sclerosis, Alzheimer's disease, Alzheimer's disease related disorders, Amyotrophic Lateral Sclerosis, Parkinson's disease, Huntington's disease, neuropathic pain, alcoholic neuropathy, alcoholism or alcohol withdrawal, or spinal cord injury.Type: ApplicationFiled: August 30, 2013Publication date: February 6, 2014Applicant: PHARNEXTInventors: DANIEL COHEN, ILYA CHUMAKOV, SERGUEI NABIROCHKIN, EMMANUEL VIAL, MICKAËL GUEDJ
-
Publication number: 20140024677Abstract: Methods and compositions for inducing mitochondrial biogenesis are provided. In some aspects, methods for the treatment of diseases such as acute kidney disease (AKI) or a muscle wasting disease by administering tomoxetine, nisoxetine, fenoterol, formoterol, or procaterol to an individual are provided.Type: ApplicationFiled: April 9, 2013Publication date: January 23, 2014Applicant: MUSC Foundation For Research DevelopmentInventors: Rick G. SCHNELLMANN, Craig C. BEESON, Yuri K. PETERSON
-
Patent number: 8633251Abstract: The subject of the invention is a group of new derivatives of aminoalkanols, more specifically [(phenoxy)alkyl]aminoalkanols and [(phenoxy)acyl)aminoalkanols, their method of obtaining and their use for production of a medicine which is used in the prophylaxis, prevention and/or treatment of diseases or symptoms having neurological background and for production of a medicine with anticonvulsant activity, which is used in seizures of various origin, also in the limbic system, in myoclonic or sound-induced seizures, in psychomotor epilepsy, as well as in relieving neuropathic or inflammatory pain.Type: GrantFiled: January 19, 2009Date of Patent: January 21, 2014Assignees: Uniwersytet JagiellonskiInventors: Henryk Marona, Anna Waszkielewicz, Katarzyna Kiec-Kononowicz
-
Patent number: 8629135Abstract: A class of compounds useful in pharmaceutical compositions and methods for treating or preventing cancer is described. The compounds' ability to inhibit RET kinase is quantified, i.e., their respective RET IC50 and EC50 values are described. One such compound, known as cyclobenzaprine and herein as SW-01, has been identified as RET-specific with an IC50 of 300 nM. SW-01 inhibits RET autophosphorylation and blocks the growth and transformation of thyroid cancer cell lines. It has been further tested in pancreatic cancer, breast cancer, and SCLC cell lines. The compounds show utility for inhibition of survival and proliferation of tumor cells.Type: GrantFiled: July 14, 2009Date of Patent: January 14, 2014Assignee: Queen's University at KingstonInventors: Taranjit S. Gujral, Lois M. Mulligan, Vinay K. Singh
-
Publication number: 20140005135Abstract: Disclosed is a stable liquid formulation for parenteral injection comprising a biocompatible non-aqueous solvent and a small molecule drug, or a salt thereof, solubilized within the non-aqueous solvent, wherein the liquid formulation comprises less than 10% by weight residual water, and wherein the volume of the liquid formulation to be parenterally injected is from 0.1 ?l to 3 ml.Type: ApplicationFiled: March 14, 2013Publication date: January 2, 2014Applicant: XERIS PHARMACEUTICALS, INC.Inventors: Steven J. Prestrelski, Nancy Scott
-
Patent number: 8618176Abstract: The present invention relates to the use of compositions comprising trans-clomiphene for treating men with hypogonadism. The invention is also directed to methods for treating males with hypogonadism.Type: GrantFiled: July 16, 2010Date of Patent: December 31, 2013Assignee: Repros Therapeutics Inc.Inventor: Joseph S. Podolski
-
Publication number: 20130317030Abstract: This invention pertains to methods and compositions for the diagnosis and treatment of cardiovascular conditions. More specifically, the invention relates to isolated molecules that can be used to diagnose and/or treat cardiovascular conditions including cardiac hypertrophy, myocardial infarction, stroke, arteriosclerosis, and heart failure.Type: ApplicationFiled: March 7, 2013Publication date: November 28, 2013Applicant: THE BRIGHAM AND WOMEN'S HOSPITAL, INC.Inventor: THE BRIGHAM AND WOMEN'S HOSPITAL, INC.
-
Patent number: 8586586Abstract: Methods and products for treating or preventing erythema or a symptom associated with erythema in a subject are described. The methods involve topically applying to an affected skin area a topical aqueous gel composition comprising about 0.01% to about 10% by weight of at least one ?-adrenergic receptor agonist and a pharmaceutically acceptable carrier.Type: GrantFiled: March 8, 2013Date of Patent: November 19, 2013Assignee: Galderma Laboratories Inc.Inventors: Michael Graeber, Christian Loesche, Philip Freidenreich, Jack A. DeJovin, Isabelle Jean DeJovin, Yin-sang Liu, Matthew James Leoni
-
Publication number: 20130303531Abstract: Disclosed are nordihydroguaiaretic acid derivative compounds including various end groups bonded by a carbon atom or heteroatom though a side chain bonded to the respective hydroxy residue O groups by an ether bond or a carbamate bond, pharmaceutical compositions, methods of making them, and methods of using them and kits including them for the treatment of diseases and disorders, in particular, diseases resulting from or associated with a virus infection, such as HIV infection, HPV infection, or HSV infection, an inflammatory disease, such as various types of arthritis and inflammatory bowel diseases, a metabolic disease, such as diabetes, a vascular disease, such as hypertension and macular degeneration, or a proliferative disease, such as diverse types of cancers.Type: ApplicationFiled: May 14, 2012Publication date: November 14, 2013Inventors: Qingqi Chen, Rocio Alejandra Lopez, Jonathan Daniel Heller, Amanda Jean Morris
-
Publication number: 20130295025Abstract: The chronic use of p-adrenergic inverse agonists such as nadolol, carvedilol, and ICI-118,551 provides an improved method for the treatment of mucus hypersecretion in subjects with such mucus hypersecretion. One aspect of a method according to the present invention is a method of preventing or controlling mucus hypersecretion in the respiratory tract comprising administering a therapeutically effective quantity of a p-adrenergic inverse agonist to a subject with mucus hypersecretion or at risk of mucus hypersecretion. The invention further encompasses pharmaceutical compositions comprising the p-adrenergic inverse agonist and the additional compound.Type: ApplicationFiled: January 9, 2012Publication date: November 7, 2013Applicant: INVION LIMITEDInventors: Richard A. Bond, Mitchell Glass
-
Publication number: 20130289118Abstract: The subject of the invention is a group of new derivatives of aminoalkanols, more specifically [(phenoxy)alkyl]aminoalkanols and [(phenoxy)acyl]aminoalkanols, their method of obtaining and their use for production of a medicine which is used in the prophylaxis, prevention and/or treatment of diseases or symptoms having neurological background and for production a medicine with anticonvulsant activity, which is used in seizures of various origin, also in the limbic system, in myoclonic or sound-induced seizures, in psychomotor epilepsy, as well as relieving neuropathic or inflammatory pain.Type: ApplicationFiled: March 29, 2013Publication date: October 31, 2013Applicant: Uniwersytet JagiellonskiInventors: Henryk Marona, Anna Waszkielewicz, Katarzyna Kiec-Kononowicz
-
Patent number: 8557817Abstract: In methods, compounds, and topical formulations for treatment of inflammatory skin disorders incorporating compounds represented by the formulas below: wherein each of R1, R2, and R3 is independently hydrogen, hologen, alkyl, or alkoxy; each of R4 and R5 is independently hydrogen, alkyl, or alkoxy; and each of R6 and R7 is independently hydrogen, nitro, alkyl, or alkoxy; wherein each of A1, A3, and A4 is independently hydrogen or alkyl; and A2 is independently hydrogen or hydroxy; and wherein each of B1, B2, and B3 is independently hydrogen, hydroxy, or alkoxy; and each of B4 and B5 is independently hydrogen or alkyl, applying such compounds topically as sprays, mists, aerosols, solutions, lotions, gels, creams, ointments, pastes, unguents, emulsions, and suspensions to treat inflammatory skin disorders and the symptoms associated therewith.Type: GrantFiled: July 10, 2012Date of Patent: October 15, 2013Assignee: Galderma Laboratories Inc.Inventors: Jack A. DeJovin, Isabelle Jean DeJovin
-
Publication number: 20130266663Abstract: Methods for treating a condition associated with proteoglycan production in a mammal are provided. The methods comprise the administration of at least one of a calmodulin antagonist, a transient receptor potential (TRP) channel inhibitor and a calmodulin-binding peptide to the mammal.Type: ApplicationFiled: April 29, 2011Publication date: October 10, 2013Inventors: Arthur Brown, Sandy Gian Vascotto
-
Publication number: 20130253064Abstract: The present invention relates generally to compositions and methods for treating neurodegenerative diseases and disorders, particularly ophthalmic diseases and disorders. Provided herein are styrenyl derivative compounds, including but not limited to stilbene derivative compounds, and compositions comprising these compounds, that are useful for treating and preventing ophthalmic diseases and disorders, including age-related macular degeneration (AMD) and Stargardt's Disease.Type: ApplicationFiled: March 7, 2013Publication date: September 26, 2013Inventors: Ian Leslie Scott, Vladimir Aleksandrovich Kuksa, Anna Gall, Mark W. Orme, Jennifer Gage, Thomas L. Little, JR., Qin Jiang, Lana Michele Rossiter, Kevin F. McGee, JR., Ryo Kubota
-
Publication number: 20130230542Abstract: Provided are compounds according to the following Formula I: The Formula I compounds are activated in the presence of reactive oxygen species (ROS) and are therefore selective anti-cancer therapeutics for cancers associated with elevated ROS. Also provided are methods and pharmaceutical compositions for treating cancers associated with increased ROS.Type: ApplicationFiled: March 1, 2013Publication date: September 5, 2013Applicants: CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER, UNIVERSITY OF CINCINNATIInventors: Edward J. Merino, James C. Mulloy, Guorui Li, Tiffany Bell-Horwath
-
Patent number: 8519005Abstract: Effects of deprenyl or propargylamine compounds (MAO inhibitors) and novel compositions comprising at least one MAO inhibitor and at least one antiinflammatory agent such as nonsteroidal antiinflammatory drugs (NSAIDS), steroids, acetaminophen (COX-3 inhibitors), 5-lipoxygenase inhibitors, leukotriene receptor antagonists, leukotriene A4 hydrolase inhibitors, antihistaminics, histamine 2 receptor antagonists, phosphodiesterase-4 antagonists, cytokine antagonists, CD44 antagonists, antineoplastic agents, 3-hydroxy-3-methylglutaryl coenzyme A inhibitors (statins), estrogens, androgens, antiplatelet agents, antidepressants, Helicobacter pylori inhibitors, proton pump inhibitors, thiazolidinediones, dual-action compounds, combinations of these drugs with other agents, derivatives and metabolites of synthetic and natural antiinflammatory agents.Type: GrantFiled: March 16, 2004Date of Patent: August 27, 2013Inventor: Thomas N. Thomas
-
Patent number: 8518918Abstract: The invention relates to novel combinations based on anticholinergics, ?2-adrenoceptor agonists, PDE 4 Inhibitors, glucocorticoids, and leukotriene-receptor antagonists, process for their production and their use for the treatment of inflammatory diseases, preferably respiratory diseases as bronchial asthma and chronic obstructive pulmonary diseases (COPD) or rheumatic or autoimmune diseases.Type: GrantFiled: September 23, 2011Date of Patent: August 27, 2013Inventors: Joachim Maus, Kastrup Horst, Istvan Szelenyi, Peter Jurgen Cnota, Bauhofer Artur
-
Publication number: 20130213398Abstract: The present invention is directed toward respirable dry particles for delivery of divalent metal cation salts and/or monovalent cation salts to the respiratory tract and methods for treating a subject having a respiratory disease and/or infection.Type: ApplicationFiled: August 26, 2011Publication date: August 22, 2013Inventors: Michael M. Lipp, Jean C. Sung, Robert W. Clarke, David L. Hava
-
Patent number: 8513249Abstract: Improved methods and compositions for safe and effective treatment of erythema or a symptom associated with erythema in a subject are described. The methods involve topically applying to an affected skin area a topical composition comprising about 0.4% to about 0.6% by weight of brimonidine and a pharmaceutically acceptable carrier.Type: GrantFiled: April 26, 2012Date of Patent: August 20, 2013Assignee: Galderma Laboratories, L.P.Inventors: Michael Graeber, Christian Loesche, Philip Freidenreich, Yin-Sang Liu, Matthew J. Leoni